Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C13H21N5O2 |
Molecular Weight | 279.3381 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](CCC3=NN=NN3)C[C@]1([H])C[C@H](NC2)C(O)=O
InChI
InChIKey=ZXFRFPSZAKNPQQ-YTWAJWBKSA-N
InChI=1S/C13H21N5O2/c19-13(20)11-6-10-5-8(1-3-9(10)7-14-11)2-4-12-15-17-18-16-12/h8-11,14H,1-7H2,(H,19,20)(H,15,16,17,18)/t8-,9+,10-,11+/m1/s1
Molecular Formula | C13H21N5O2 |
Molecular Weight | 279.3381 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Tezampanel, also known as LY 293558 and NGX-424, is a drug originally developed by Eli Lilly, which is a competitive antagonist of the AMPA and kainate subtypes of the ionotropic glutamate receptor family. Tezampanel was in phase II clinical trial for treatment migraine, but this study was discontinued. Also this drug has several others potential pharmacological actions, one of them is anxiety disorders
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23042954
Curator's Comment: Known to be CNS penetrant in rat. Human data not available
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2109241 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8609884 |
|||
Target ID: CHEMBL2096670 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7760975 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18433 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23042954 |
15 mg/kg single, intramuscular dose: 15 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered: |
TEZAMPANEL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9396 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23042954 |
15 mg/kg single, intramuscular dose: 15 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered: |
TEZAMPANEL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23042954 |
15 mg/kg single, intramuscular dose: 15 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered: |
TEZAMPANEL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. | 1998 Nov |
|
Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. | 2001 |
|
Differential involvement of NMDA, AMPA/kainate, and dopamine receptors in the nucleus accumbens core in the acquisition and performance of pavlovian approach behavior. | 2001 Dec 1 |
|
Amygdala regulation of nucleus accumbens dopamine output is governed by the prefrontal cortex. | 2001 Jan 15 |
|
Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. | 2001 May 7 |
|
LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. | 2001 Oct |
|
LY-293558. Eli Lilly & Co. | 2001 Sep |
|
Dissociable effects of antagonism of NMDA and AMPA/KA receptors in the nucleus accumbens core and shell on cocaine-seeking behavior. | 2001 Sep |
|
AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa. | 2002 Dec |
|
Extradural compression of sensorimotor cortex: a useful model for studies on ischemic brain damage and neuroprotection. | 2002 Jan |
|
Effect of intrathecal non-NMDA EAA receptor antagonist LY293558 in rats: a new class of drugs for spinal anesthesia. | 2002 Jul |
|
Effect of bilateral hypogastric nerve transection on voiding dysfunction in rats with spinal cord injury. | 2002 May |
|
Glutamate receptors in the rat medial prefrontal cortex regulate set-shifting ability. | 2003 Aug |
|
Distinct contributions of glutamate receptor subtypes to cognitive set-shifting abilities in the rat. | 2003 Nov |
|
Direct interactions between the basolateral amygdala and nucleus accumbens core underlie cocaine-seeking behavior by rats. | 2004 Aug 11 |
|
LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. | 2004 Jul |
|
Supraspinal and spinal alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid and N-methyl-D-aspartate glutamatergic control of the micturition reflex in the urethane-anesthetized rat. | 2005 |
|
Histaminergic modulation of excitatory synaptic transmission in the rat basolateral amygdala. | 2005 |
|
Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging. | 2005 Aug |
|
AMPA/kainate, NMDA, and dopamine D1 receptor function in the nucleus accumbens core: a context-limited role in the encoding and consolidation of instrumental memory. | 2005 May-Jun |
|
In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. | 2006 Apr |
|
Reflexes evoked by electrical stimulation of afferent axons in the pudendal nerve under empty and distended bladder conditions in urethane-anesthetized rats. | 2006 Jan 15 |
|
The effect of the AMPA/kainate receptor antagonist LY293558 in a rat model of postoperative pain. | 2006 Oct |
|
Epidural tezampanel, an AMPA/kainate receptor antagonist, produces postoperative analgesia in rats. | 2007 Oct |
|
Gateways to clinical trials. | 2008 Oct |
|
Fractionating spatial memory with glutamate receptor subunit-knockout mice. | 2009 Dec |
|
Regulation of AMPA receptors in spinal nociception. | 2010 Jan 21 |
|
Suppression of stretch reflex activity after spinal or systemic treatment with AMPA receptor antagonist NGX424 in rats with developed baclofen tolerance. | 2010 Nov |
|
Spasticity therapy reacts to astrocyte GluA1 receptor upregulation following spinal cord injury. | 2010 Nov |
|
A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonists. | 2015 Apr 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00567086
Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16470401
LY293558 (Tezampanel) had a rank order of potency of GLU(K5) > or = GLU(K5/6) approximately GLU(A2i) approximately GLU(K2/5) approximately GLU(A1i) approximately GLU(A2o) approximately GLU(A3i) approximately GLU(A1o) > or = GLU(A3o) > or = GLU(A4i) approximately GLU(A4o) and >100 microM affinity for rat cortical GABA(A) receptors. Comparison of the blockade of AMPA- vs N-methyl-D-aspartate (NMDA)-induced inward currents demonstrated that LY293558 was five-fold more potent as an antagonist at AMPA vs NMDA receptors in vitro.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:01:12 GMT 2023
by
admin
on
Fri Dec 15 16:01:12 GMT 2023
|
Record UNII |
GA36S2O9C2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47795
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GA36S2O9C2
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
PRIMARY | |||
|
8743
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
PRIMARY | |||
|
C80379
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
PRIMARY | |||
|
154652-83-2
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
PRIMARY | |||
|
TEZAMPANEL
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
PRIMARY | |||
|
127894
Created by
admin on Fri Dec 15 16:01:12 GMT 2023 , Edited by admin on Fri Dec 15 16:01:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |